Jaguar Health Subsidiary Napo Pharmaceuticals Expands Mytesi Salesforce With Hire of Experienced HIV & GI Drug Sales Reps in Key U.S. Markets
New Reps Will Target Physicians and Gastroenterologists Who Treat Large Numbers of HIV Patients
Napo’s new sales representatives are based in and will cover
“We’re very pleased to have hired a team of top-notch sales personnel to
represent Mytesi® in these highly important markets,”
Napo’s new in-house sales team will replace the external, part-time
national Mytesi® salesforce Napo established as an outsourced
effort in February of this year. Mytesi® net sales to-date in
2017 total approximately
Mytesi® is approved by the U.S.
"The medical need for a product like Mytesi®—which
offers a novel mechanism of action and has been demonstrated to be safe
and effective for its current, approved indication—is significant,
compelling, and unmet. Napo launched Mytesi® in early 2017
with one full-time-equivalent sales representative focused on targeting
HIV doctors who are high-volume prescribers of antiretroviral therapies.
With the equivalent of seven dedicated, full-time sales representatives
reporting to our newly hired national sales manager, supported by
concomitant marketing and promotional activities, as well as medical
education initiatives—such as the poster presentation Napo conducted at
Mytesi® is currently covered by
Mytesi® (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are available at Mytesi.com.
Crofelemer, the active ingredient in Mytesi®, is a botanical
(plant-based) drug extracted and purified from the red bark sap of the
medicinal Croton lechleri tree in the
Certain statements in this press release constitute “forward-looking statements.” These include statements regarding the development of potential Mytesi® follow-on indications, and the expectation that Napo’s sales representatives, supported by the Company’s marketing, promotional activities, and medical education initiatives, will generate a proportional response in the number of patients treated with Mytesi®. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
KCSA Strategic Communications
Garth Russell, 212-896-1250